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Abstract
Background: The application of highly active antiretroviral therapy (HAART) against
HIV can reduce and maintain viral load below detection limit in many patients.
Continuous HAART, however, can have severe side effects. In this context, structured
treatment interruptions (STI) were considered to be a promising strategy. However,
using CD4 cell count to guide intermittent therapy starting and stopping points, the
SMART study (strategies for management of antiretroviral therapy), revealed that STI
were associated with increased risk of AIDS and other complications. Additionally,
short-term periodic (e.g. one week on / one week off) interruption therapies have
shown virus rebound exceeding a given “failure threshold”, without any evidence for
the evolution of drug resistance. Currently, the only hypothesis explaining the failure of
STI is the “resonance hypothesis”, which posits that treatment failure is due to a
resonance effect between the drug treatment and the viral population. In the present
study we used a mathematical model to analyse the parameters affecting the output of
drug treatment interruption and the premises of the resonance hypothesis.
Methods: We used a population dynamic model of HIV infection. Simulations and
analytical approximations of deterministic and stochastic versions of the model were
studied.
Results and Conclusion: The present study examines the roles of the most important
parameters affecting the viral rebound, responsible for drug failure. We related these
findings to the resonance hypothesis, and showed that the degree of sustainability of
damping oscillations present in the model after the acute phase is strongly linked to
their amplitude, which determines the resonance level. Stochastic simulations of the
same model even revealed sustained oscillations in virus population for small virus
population sizes. Given that pronounced viral load oscillations have not been observed
in HIV-1 patients, the link between oscillations and resonance level suggests that
treatment failure due to a resonance effect is not plausible. Moreover, the failure
threshold is attained before the virus population crosses the set point while growing. As
the maximum virus population is reached even after the set point is crossed, the role of
resonance effects in the context of treatment interruptions cannot explain drug failure.
Background
HIV infection is characterised by an exponential increase of the virus population during
a so-called acute phase, which is followed by a decrease, before reaching a (more or less
fluctuating) steady state, called set point. This steady state characterises the asymptomatic
phase. At this stage, the viral load can vary more than 1000-fold between patients [1].
Drug therapy often decreases the virus population to lower, almost undetectable levels
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[2]. When drug administration is interrupted, the virus population increases at different
rates in each patient.
The combined administration of different types of drugs, known as highly active
antiretroviral therapy (HAART), can reduce and maintain viral load below detec-
tion limit in many patients. The introduction of HAART methods have thereby dra-
matically improved the average prognosis of HIV infections. However, in addition
to having potentially toxic side effects, drugs can also be inaccessible due to cost
[3,4]. Structured Treatment Interruptions (STI), consisting of therapy withdrawal and
re-initiation according to specific criteria, has been proposed to reduce these prob-
lems [5,6]. The protocols vary from non-periodic randomised controlled trials [7],
to the most common, a periodic one week on/one week off scheme [3,4]. Although
this method has shown some degree of success [3,4,8-10], an important large-scale
study showed failure in half of the cases [8]. Failure occurs when the viral rebound
exceeds a given “failure threshold”, and is apparently not caused by virus resistance
[8]. On the other hand, by using CD4 cell count to guide intermittent therapy start-
ing and stopping points, the National Institute of Health’s Strategies for Management
of Antiretroviral Therapy (SMART) study [11], revealed that STI was associated with
increased risk of AIDS or death, serious AIDS-defining events, and other severe
complications.
Although STI has, in recent years, become an obsolete approach to cope withHIV infec-
tions, the investigation of the viral population dynamics after drug interruption can still
offer valuable insights. Any perturbation of the system can provide information about the
forces underlying the population biology of the virus, and can also shed light on current
problems of HAART such as the consequences of drug interruption resulting from low
drug adherence.
A prominent hypothesis states that resonance effects between virus oscillations and
the administered drug treatment account for the failure of STI [12]. By studying patient-
specific resonance spectra (including the maximal, minimal and average viral response
to different times of drug administration and interruption), the authors found pat-
terns in agreements with empirical observations, e.g. that two patients with similar
initial set points can present different virological responses. One of the weaknesses
of the resonance hypothesis is the requirement that an oscillatory behaviour should
exist in the HIV population within patients. Although the authors do not specify the
relationship between the resonance effect and the oscillations, they acknowledge that
the resonance hypothesis is speculative because oscillations have not been observed in
HIV [12].
In this study, we used the population dynamic model underlying the resonance
hypothesis to derive the most important parameters affecting the viral rebound. We
have classified the parameters into those that affect the viral set point, those that
affect the viral rebound rate, and those that alter both. We have then studied the
relationship between the amplitude of the resonance oscillations – present in the
model after the acute phase – and their degree of sustainability. We have also eval-
uated the effect of stochasticity on the oscillations for different viral population
sizes. Finally, we have analysed the relationship between the failure threshold, the
viral set point, and the viral rebound rate with regard to their role in the failure
of STI.
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Materials andmethods
The basic model of HIV-virus dynamics [13-15] has three variables: uninfected cells, x;
infected cells, y; and free virus particles, v, and is given by the following set of differential
equations:
x˙ = λ − dx − βxv (1)
y˙ = βxv − ay (2)
v˙ = ky − uv (3)
Uninfected cells are produced at a constant rate, λ, and die at the rate dx. Free
virus infects uninfected cells to produce infected cells at rate βxv. Infected cells die
at rate ay. New virus is produced from infected cells at rate ky and dies at rate
uv. Therefore, the average life-times of uninfected cells, infected cells, and free virus
are thus given by 1/d, 1/a, and 1/u, respectively. The average number of virus par-
ticles produced over the lifetime of a single infected cell (the burst size) is given
by k/a [13]. The virus variable v, defines the total amount of virus particles that
are able to infect uninfected cells, and therefore generate cell-to-cell transmission,
after a complete round of infection including proper integration in the infected cells.
The basic reproductive ratio, R0, is defined as the average number of newly infected
cells that arise from any one infected cell when almost all cells are uninfected. Here
R0 = βλk/(adu).
We performed both deterministic and stochastic simulations of this model. The
stochastic simulations were performed employing an exact approximation using the Gille-
spie algorithm [16] and for large population sizes we used Tau Leap binomial methods
[17]. The analytical equivalence between the stochastic and the deterministic formulation
is presented in the Additional file 1.
Results
The resonance effect
In this section we reviewed the analysis from Breban and Blower [12], and summarised
their results, proposing a quantitative measurement for the resonance level.
Numerical simulations of the model given by Equations (1-3) show that there can be a
significant rebound of virus load after drug interruption only under certain specific con-
ditions. Moreover, the strength of the viral rebound depends on the selected parameters.
Here, each parameter combination represents a (simulated) patient [12].
The “resonance spectra” plots for each patient, ([12]; Figure two) includes the mini-
mum, maximum, and average viral load at different periods of STI. These plots show that
patients can begin with similar set points, but end up with very different maximum viral
population size values after drug interruption, or the opposite: very different set points,
but similar levels of the maximum viral population size after drug interruption. The larger
the width between the set point and the maximum value of the viral population size, the
higher the resonance [12]. Therefore, the resonance level can be simply quantified as the
ratio between this maximum and the set point. This ratio summarises the measurements
from the spectra given in [12], as it is shown in Figure 1.
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Figure 1 Simulation of viral load and the effect of drug interruption over time (A) and as a function of
the period of STI (B). Shaded areas represent the intervals of time on treatment, modelled as a decrease by
30 % in β and k as in [12]. Red and blue are the patients A and B from [12]. Patient A: λ = 20, d = 0.02,
a = 0.4, u = 4.0, β = 5 10−5, k = 100, and patient B, as A except β = 8 10−5. The level of resonance (R) is
defined by the ratio of a (the maximum value attained by the virus population) and b (the viral set point).
Parameters defining different viral loads
The resonance effect was proposed using the model given by Equations (1-3) [12] and
using the parameters from a previous study [18]. Notably, the parameter values used vary
significantly among different studies (see Table 1), resulting in a variation of the viral set
point by several orders of magnitude, possibly reflecting the variation observed in empir-
ical studies. Indeed, empirical studies have shown that the viral load at the set point varies
enormously between patients and is correlated with the duration of the asymptomatic
phase of HIV (and thus the development of AIDS) [19]. Therefore, the progression of the
disease can be predicted, to some extent, by the set point. However, it is not clear whether
the set point is related to the drug treatment failure.
Table 1 summarises the set of parameters used by different authors and are classified
here as parametrisation I, II, III, and IV according to their values. In particular, parametri-
sation II provided the basis for postulating the resonance effect as the cause of drug
failure [12].
Resonance level and oscillations
One of the main topics addressed in the present study is the relationship between reso-
nance and oscillations. Specifically, we were interested in the possible link between the
amplitude of the oscillations generated by the model after drug treatment is withdrawn
(mainly the first peak of the virus rebound) and the degree of sustainability of the oscil-
lations (i.e. the number of oscillations needed to approach the steady state). This last
Table 1 Different biological parameters used in the literature
Parametrisation Parameter values Virus load at steady References
state (per day per mL)
I λ = 10, d = 0.1, a = 0.5
u = 3, β = 0.01, k = 10 v∗ = 65.67 [15,20]
II λ = 20, d = 0.02, a = 0.4
u = 4, β = 5.10−5, k = 100 v∗ = 850 [12,18]
III λ = 105, d = 0.1, a = 0.5
u = 5, β = 2.10−7, k = 100 v∗ = 3.5 106 [15]
IV λ = 107, d = 0.1, a = 0.5
u = 5, β = 5.10−10, k = 500 v∗ = 1.8 109 [13]
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measure can be quantified as the ratio of the imaginary part and the real part of the
complex eigenvalues, present in a system exhibiting damped oscillations [21]. Since the
analytical expressions of the eigenvalues are too intricate to be studied, we simulated
random variations of the parameters (taken from a uniform distribution) around their
original value for each parametrisation I, II, III, and IV. If the original parameter value is
p, then the new parameter values will be in a range p ± pα, where α = 0.7. The resulting
parametrisations were selected to fulfill the following requirements: (1) positive equilibria
of the populations involved (free virus, non-infected cells and infected cells), (2) negative
real part of the eigenvalues for a stable equilibrium, (3) some of the eigenvalues of the
Jacobian matrix of the system (1-3) should be complex, to ensure that the equilibrium is
reached after damped oscillations [21].
A simple way to quantify the resonance level is to calculate the ratio between the
maximum value of virus load after drug interruption and the viral set point. That is:
R = max(v(t))v∗ (4)
The value R therefore quantifies the resonance level in the virus population.
The degree of sustainability of the oscillations () is given by the relationship between
the absolute value of the imaginary and the real part of the eigenvalues of the Jacobian
matrix of the system (1-3):
 = |Im(Eigenvalues)||Re(Eigenvalues)| (5)
Figure 2A and B, show the effect of the set-point virus load and of , on the resonance
level (R) for 104 simulated patients. Consistent with Breban and Blower [12], we can see
in Figure 2A that similar set point virus loads can exhibit different resonance levels. How-
ever, we also found that there is a tight correlation between the degree of sustainability
of oscillations and the resonance level (Figure 2B). Therefore, according to the resonance
hypothesis, drug failure should be observed in systems that exhibit sustained oscillations.
Parametrisation II
Viral Set Point Degree of sustainability 





Figure 2 Resonance level of random examples generated from parametrisation I (orange), II (red), III
(green) and IV (blue). Figure A shows the distribution of the samples generated for different viral set points,
and the position of parametrisation II. Figure B shows the correlation between the degree of sustainability of
the oscillations () and the resonance level (R).
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Damped and sustained oscillations
The parametrisation II analysed in [12] has two important characteristics: a) soft damp-
ing, and therefore high resonance level (as showed in Figure 2) B, and b) small virus
population size.When the population size is small, the effect of stochastic forces becomes
more important. Evidence from other ecological and epidemiological systems have shown
that models exhibiting damped oscillations in a deterministic approximation can present
sustained oscillations driven by stochastic forces [22-25].
A full description of the process given by Equations (1-3) can be achieved consider-
ing each term as a probabilistic event (see Additional file 1). This formulation results
in a master equation that can be expressed as a series expansion. The first order of
the series corresponds to the deterministic system given by Equations (1-3). Higher
orders become important when the population size is small (i.e. when the noise is
high). In Figure 3, we show the effect of considering higher orders using a dynamic
Monte Carlo simulation. We found that for the parameter values of parametrisation
II, which result in a small viral set point, stochasticity induced sustained oscillations
(Figure 3A). In Figure 3B we show that this effect depends on the population size: by
changing λ and β , but keeping the basic reproductive ratio of the virus (R0) constant,
we observed that the oscillations became damped. The difference between Figure 3A
and 3B. can be described as follows: in deterministic systems, damped oscillations are
characterised in the phase space by an unstable limit cycle (located in the vicinity of the
first maximum and minimum values of the damping oscillations), and a stable equilib-
rium point (given by the steady state -in this case, known as the viral set point). The
noise is higher in systems where the population size is small, and stochasticity effec-
tively maintains the oscillatory regime around the unstable limit cycle. On the contrary,
when the population size is large, stochasticity maintains the system far from the unsta-
ble limit cycle, and fluctuates instead in the proximity of the stable equilibrium point
(the set point). This difference is important, since resonance is dependent on the dis-
tance between the maximum values attained by the viral population and the average
values (set point). Both scenarios shown in Figure 3 are valid stochastic versions of the
parametrisation II analysed in [12]. Which version (Figure 3A or Figure 3B) is considered
more realistic, depends on the magnitude of stochastic effects in HIV, which is heavily
debated [26].


















Time (days) Time (days)
BA
Figure 3 Viral load over the time in the deterministic (red), and stochastic (blue) model. A. The
parameters are: λ = 20, d = 0.02, a = 0.4, u = 4, β = 5.10−5, k = 200 (patient ‘C’ from [12]). For these
parameters, stochastic dynamics induce sustained oscillations. B. For λ = 2000, and changing β to maintain
the same R0 (β = 0.05/(λ/d)), the oscillations are damped.
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Parameters affecting viral rebound and limitations of the resonance hypothesis
One could argue that the validity of the resonance hypothesis is restricted to an unreal-
istic parameter range. We considered two scenarios: failure threshold above the set point
(Figure 4A and B) or failure threshold below the set point (Figure 4C and D). The first sce-
nario is not plausible because, in the absence of drug therapy, the viral population at the
set point is already below the failure threshold. Therefore, according to the treatment cri-
teria chosen here, the patient should not have received therapy in the first place. Notably,
this is the only scenario in which the resonance hypothesis holds. In a more realistic case,
the failure threshold is below the viral set point (in fact, the empirical work upon which
the resonance hypothesis is based, considers a failure threshold of 500 virus copies/ml
[8]). As a consequence, the amplitude of the oscillations or the maximum value reached
by the viral rebound does not affect drug failure. This indicates that drug failure is deter-
mined by the rate at which the viral population is growing during the exponential phase
of viral rebound and, more specifically, how fast it reaches the “failure threshold”.
Although it is not possible to derive an analytical solution for the system given by dif-
ferential Equations (1-3), an effective analytical approximation for the exponential phase
of viral rebound can be obtained [15]. After drug interruption, the viral basic reproduc-
tive ratio is R0 >> 1. In these circumstances, the exponential phase of viral rebound after
drug interruption can be approximated by:
v(t) = v0e βλkdu t (6)
Figure 4 Schematic illustration of the different possible relations between the viral set point and the
failure threshold. In Figure A and B the failure threshold is above the set point. In Figure A a strong resonant
case generate a peak in viral load reaching the failure threshold. In Figure B the viral rebound do not reach
the failure threshold. Figure C and D show a scenario where the failure threshold is below the set point. In
this case the exponential viral rebound, crossing the failure threshold, determines the time of drug failure.
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The virus set point is given by:
v∗ = λkau (7)
From Equations (6) and (7) we derive two predictions. First, if two patients differ only
in λ, k or u, we expect a correlation between v(t) and v∗. Second, if two patients differ
only in β , a and d, then we expect no correlation between v(t) and v∗. These relation-
ships explain why patients who have similar viral set points can have different responses
to STI.
Discussion
Resonance phenomena in biological systems are a dynamic area of research, with
potential applications in different biological fields [27,28]. To our knowledge, the res-
onance hypothesis has been the only theoretical explanation proposed for drug fail-
ure under STI when such failure cannot be accounted for by viral resistance. The
resonance hypothesis proposes that, after the interruption of drug therapy, the viral
population reaches a maximum level, not correlated with the viral set point. There-
fore, this hypothesis can account for cases in which two patients with similar set
points at the outset, can result in STI failure in one patient and success in the other.
The proponents of the hypothesis have acknowledged the speculative nature of the
resonance hypothesis owing to the fact that viral oscillations have not been observed
in HIV patients [12] –indeed, empirical data suggests that the pattern of virological
decay and cumulative viral load after antiretroviral therapy in HIV-infected subjects
is characterised by damped oscillation in the viral load [29] –. However, no detailed
analysis has been made on the relationship between the proposed failure caused by
the maximum of viral growth and the degree of sustainability of the viral oscilla-
tions. Also, it should be mentioned that even one single interruption in the drug
administration produces the increase of the viral load, which indicates that the period-
icity in drug administration does not seem to be necessary for the “resonance effect”
to be observed.
Using a deterministic description of the model, we have shown that, for con-
ditions in which the resonance effect is strong, oscillations are weakly damped
(Figure 2B). We showed that a full description of the process, including stochas-
tic effects, exhibited a sustained oscillatory regime for small viral population sizes
(Figure 3A). Since weakly damped oscillations have not been observed in HIV-1
patients [14], the strong correlation between the degree of sustainability of oscilla-
tions and the resonance level suggests that the resonance hypothesis is not plausible.
For some parameter regions, the model exhibits behaviour in line with empirical
observations, namely a strong damping of oscillations. In these cases, the maximum
viral rebound tends to be small. Finally we find that the viral peak reached after
therapy interruption is attained after the viral population reaches the failure thresh-
old. Therefore, in order to characterise the process that drives to drug failure, one
should focus on the exponential rate of viral growth that occurs after drug interrup-
tion. The parameters of the model influencing this phase was presented and classified
into those that affect the viral set point, those that affect the viral rebound rate,
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and those that alter both. We have shown that the basic model of virus dynam-
ics can also account for the pattern of failure and success on patients with similar
set points.
Further biological factors can influence the interaction between drug administration
and HIV dynamics, as well as determine the viral set point. One important biological
factor to consider is the cellular reservoir. HIV particles can remain in latent cells, con-
ferring a reservoir for the virus that is not affected by drug treatment. The presence
of a viral cellular reservoir will affect the plasma viral load to an extent that depends
on the efficacy of the drug, and on the magnitude of latent cell activation [30]. A com-
parative approach using different types of models, which explicitly includes biological
delays and latent cells, can be found in Holder and Beauchemin [31]. Another bio-
logical factor to consider is the immune response, which can play an important role
determining the set point and the viral rebound rate. Including in the model spatial
dynamics and delays in the interaction terms between cells and viral population can
play a role in increasing or decreasing oscillations. However, we performed all analyses
using the same model as the proponents of the resonance hypothesis. The rationale is
that mathematical models provide a precise and explicit connection between assump-
tion and conclusion. By including more complexity in the model, the assumptions and
therefore the conclusions will be different. The use of the basic model has enabled
us to provide a general picture of the pattern observed for HIV dynamics, and has
allowed us to explore the consequences of the assumptions of the resonance hypothesis.
In addition, it has provided an opportunity to analytically study the crucial param-
eters determining drug failure that occurs during the exponential phase of the viral
rebound.
From a clinical perspective, our results explain how different patients can have sim-
ilar initial viral set points but can differ in responses to therapy interruptions, without
a resonance effect between the pattern of drug administration and the viral population
dynamics. In fact, this effect is observable even in a single event of drug interruption.
Therefore, given that the viral rebound caused by drug interruption does not require any
periodicity in the drug administration, the mechanistic reason of the “treatment failure”
described in the present study by viral rebound, can also be present as a consequence of
low drug adherence. Therefore, although STI is not recommended in any patient infected
with HIV, regardless of clinical status, the implications of the virological failure observed
in empirical data from STI studies, along with the theoretical work that has emerged to
explain the mechanistic basis of such failure, can also inform related topics, such as the
consequences of low drug adherence. In this respect, further studies need to address ques-
tions regarding the effects of drugs with diverse kinetic parameters in combination with
different levels of drug adherence on treatment failure by simple viral rebound or by the
evolution of drug resistance [32].
Conclusion
In the present study we combined deterministic and stochastic models of HIV infection
to investigate the causes of drug failure observed in STI. We found evidence against the
resonance hypothesis, which proposes that drug failure is caused by a resonance effect
between the pattern of drug administration and the viral dynamics of HIV. We studied
the parameters affecting the viral set point and viral rebound. Our analysis enabled us to
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establish the crucial parameters which determine the drug failure that occurs during the
exponential phase of the viral rebound.
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